Nantcell, Inc.

This early-stage study tested a new cancer vaccine designed to teach the body's immune system to recognize and attack tumors. It involved 43 people with advanced colorectal, lung, breast, or prostate cancer that had stopped responding to standard treatments. The main goals were t…